H. Küpper

7.7k citations

127 papers · 5.8k indexed · 2 hit papers · h-index 37

Impact in

Rheumatology top 0.05%
- Rheumatoid Arthritis Research and Therapies
- Spondyloarthritis Studies and Treatments
- Systemic Lupus Erythematosus Research
Hematology top 0.5%
- Autoimmune and Inflammatory Disorders Research

Papers in

Rheumatology 83
- Rheumatoid Arthritis Research and Therapies 71
- Spondyloarthritis Studies and Treatments 28
- Systemic Lupus Erythematosus Research 14
Hematology 59
- Autoimmune and Inflammatory Disorders Research 56

Co-authors: Robert Wong Désirée van der Heijde Joachim Sieper S. Kary Martín Rudwaleit Jürgen Braun Alan Kivitz Maxime Dougados
Journals: Annals of the Rheumatic Diseases (32 papers)Lara D. Veeken (14 papers)The Journal of Rheumatology (8 papers)Arthritis Research & Therapy (5 papers)Arthritis & Rheumatology (4 papers)
Partner nations: Germany United States Netherlands

In The Last Decade

H. Küpper

118 papers receiving 5.6k citations

Hit Papers

align trajectories log scale

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trial 2006 · 660 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2006 Arthritis & Rheumatism
2004 Annals of the Rheumatic Diseases

Peers

Countries citing papers authored by H. Küpper

Since Specialization

Citations

This map shows the geographic impact of H. Küpper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Küpper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Küpper more than expected).

Fields of papers citing papers by H. Küpper

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Küpper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Küpper. The network helps show where H. Küpper may publish in the future.

Co-authors

The 25 scholars most cited alongside H. Küpper, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with H. Küpper Line = papers co-authored together H. Küpper links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A first‐in‐human study of the novel immunology antibody–drug conjugate, ABBV‐3373, in healthy participants British Journal of Clinical Pharmacology ·Ronilda D’Cunha, H. Küpper, Dilek Arikan, Weihan Zhao, David Carter, Jonas Blaes, Melanie C. Ruzek, Yinuo Pang	2023	6
2	Efficacy and Safety of ABBV‐3373, a Novel Anti–Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody–Drug Conjugate, in Adults with Moderate‐to‐Severe Rheumatoid Arthritis Despite Methotrexate Therapy: A Randomized, Double‐Blind, Active‐Controlled Proof‐of‐Concept Phase IIa Trial Arthritis & Rheumatology ·Frank Buttgereit, Jacob Aelion, Bernadette Rojkovich, Anna Zubrzycka‐Sienkiewicz, Su Chen, Yang� Yang, Dilek Arikan, Ronilda D’Cunha, Yinuo Pang, H. Küpper, Timothy R. D. J. Radstake, Howard Amital	2022	31
3	Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial Clinical Therapeutics ·Sandra Goss, Cheri E. Klein, Ziyi Jin, Charles Locke, Ramona Rodila, H. Küpper, Gerd‐Rüdiger Burmester, Walid M. Awni	2018	13
4	Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial Annals of the Rheumatic Diseases ·Gerd‐Rüdiger Burmester, Alan Kivitz, H. Küpper, Udayasankar Arulmani, S. Florentinus, Sandra Goss, Suchitrita S. Rathmann, Roy Fleischmann	2014	183
5	Long-Term Impact of Delaying Combination Therapy With Adalimumab Plus Methotrexate By 2 Years in Patients With Early Rheumatoid Arthritis: Final 10-Year Results of the Premier Trial Data Archiving and Networked Services (DANS) ·E C Keystone, F. C. Breedveld, D. van der Heijde, Robert Landewé, S. Florentinus, Udayasankar Arulmani, S.F. Liu, H. Küpper, Arthur Kavanaugh	2013	1
6	Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial The Lancet ·Josef S Smolen, Paul Emery, Roy Fleischmann, Ronald van Vollenhoven, Karel Pavelká, Patrick Durez, B. Guérette, H. Küpper, Laura Redden, Vineet M. Arora, Arthur Kavanaugh	2013	210
7	Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan Clinical Rheumatology ·Tomoyuki Imagawa, Syuji Takei, Hiroaki Umebayashi, Kenichi Yamaguchi, Yasuhiko Itoh, Toshinao Kawai, Naomi Iwata, Takuji Murata, Ikuo Okafuji, Mari Miyoshi, Yasuhiro Onoe, Yoshifumi Kawano, Noriko Kinjo, Masaaki Mori, Neelufar Mozaffarian, H. Küpper, Sourav Santra, Gina Patel, Shinichi Kawai, Shumpei Yokota	2012	58
8	Initial Combination Therapy with Adalimumab Plus Methotrexate Leads to Better Long-Term Outcomes in Patients with Advanced Rheumatoid Arthritis: Analysis of the Final 10-Year Results of An Open-Label Extension of a Phase 3 Trial Data Archiving and Networked Services (DANS) ·Edward Keystone, D. van der Heijde, M. Weinblatt, Neelufar Mozaffarian, B. Guérette, H. Küpper, S.F. Liu, B M Wolfe, Arthur Kavanaugh	2011	1
9	Initial Combination Therapy with Adalimumab Plus Methotrexate Leads to Better Long-Term Outcomes Than with Either Monotherapy in Patients with Early Rheumatoid Arthritis: 8-Year Results of An Open-Label Extension of a Phase 3 Trial Data Archiving and Networked Services (DANS) ·F. C. Breedveld, Edward Keystone, D. van der Heijde, Robert Landewé, J S Smolen, B. Guérette, M. McIlraith, H. Küpper, S.F. Liu, B M Wolfe, Arthur Kavanaugh	2011	5
10	Maintenance of reduction in disease activity and partial remission in patients with Ankylosing spondylitis (AS) - 3-year results from the adalimumab (HUMIRO) trial evaluating long-term efficacy and safety in AS (ATLAS) Oxford University Research Archive (ORA) (University of Oxford) ·Désirée van der Heijde, Ben A. C. Dijkmans, M. Schiff, A. Kivitz, Kurt De Vlam, P Wordsworth, Shaila Ballal, H. Küpper, Randi Wong, J. Sieper, Grp Atlass.	2008	2
11	Predictors of good clinical response (BASDAI 50 or ASAS partial remission) in 1,250 patients treated with adalimumab (humira (R)) for active ankylosing spondylitis (AS) Clinical and Experimental Rheumatology ·Martín Rudwaleit, Pascal Claudepierre, P Wordsworth, Estíbaliz Loza, Ruey‐Hong Wong, M. Kron, S. Kary, H. Küpper	2008	2
12	Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve‐week randomized, double‐blind, placebo‐controlled trial followed by an open‐label extension up to week fifty‐two Arthritis & Rheumatism ·Hildrun Haibel, Martín Rudwaleit, Joachim Listing, F. Heldmann, Robert Wong, H. Küpper, Jürgen Braun, Joachim Sieper	2008	231
13	Effect of the early use of the anti–tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis Arthritis Care & Research ·Victoria Bejarano, Mark Quinn, Philip G. Conaghan, Richard J. Reece, Anne‐Maree Keenan, David Walker, Andrew Gough, Michael Green, Dennis McGonagle, Ade Adebajo, Stephen Jarrett, Sheelagh Doherty, Lesley Hordon, R D Melsom, Kristina Unnebrink, H. Küpper, Paul Emery	2008	136
14	Remission and major clinical response in active rheumatoid arthritis (RA) patients after adalimumab (Humira (R)) treatment Lara D. Veeken ·Gerd-R. Burmester, P Wordsworth, Frank McKenna, G F Farraccioli, Flipo Rm, S. Kary, H. Küpper	2007	1
15	Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice Lara D. Veeken ·Stefano Bombardieri, A. A. Ruiz, Patrice Fardellone, Piet Geusens, Frank McKenna, Kristina Unnebrink, U. Oezer, S. Kary, H. Küpper, G. R. Burmester	2007	153
16	Treatment with adalimumab reduces signs and symptoms and induces partial remission in patients with ankylosing spondylitis (AS): 1-year results from ATLAS. Oxford University Research Archive (ORA) (University of Oxford) ·Désirée van der Heijde, A. Kivitz, Michael Schiff, J. Sieper, Dijkmans Bac., Jürgen Braun, Maxime Dougados, P Wordsworth, Randi Wong, H. Küpper, John W. Davis	2006	4
17	Efficacy and safety of adalimumab (Humira (R)) in European clinical practice: The ReAct trial Lara D. Veeken ·G. R. Burmester, P Wordsworth, Xavier Mariette, Indalecio Monteagudo Sáez, Bijlsma Jwj., Declan Webber, H. Küpper	2005	0
18	Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study Critical Care Medicine ·Konrad Reinhart, T. Menges, Bengt Gårdlund, Jan H. Zwaveling, Mark Smithes, Jean‐Louis Vincent, José M. Tellado, Antonio Salgado-Remigio, Reuven Zimlichman, Stuart Withington, Klaus Tschaikowsky, Rainer Brase, Pierre Damas, H. Küpper, J. Kempeni, Juergen Eiselstein, Martin Kaul	2001	180
19	A SINGLE DOSE PLACEBO CONTROLLED PHASE I STUDY OF THE FULLY HUMAN ANTI-TNF ANTIBODY D2E7 IN PATIENTS WITH RHEUMATOID ARTHRITIS Arthritis & Rheumatism ·Leo van de Putte, Piet L. C. M. van Riel, Alfons A den Broeder, Oliver Sander, Rolf Rau, Christina Binder, Klaus Krüger, M Schattenkirchner, Helmut Fenner, Jochen Salfeld, Y. Bankmann, H. Küpper, J. Kempeni	1998	21
20	[Epitope analysis of CD68 antigens]. PubMed ·D Ulsijchutagijn, H. Küpper, Wd. Eichler, Helmut Fiebig	1991	1

About H. Küpper

H. Küpper is a scholar working on Rheumatology, Hematology, Genetics, Speech and Hearing and Immunology, having authored 127 papers that have together received 5.8k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (71 papers), Autoimmune and Inflammatory Disorders Research (56 papers), Chronic Lymphocytic Leukemia Research (30 papers), Spondyloarthritis Studies and Treatments (28 papers), Lymphoma Diagnosis and Treatment (21 papers), Psoriasis: Treatment and Pathogenesis (17 papers), Systemic Lupus Erythematosus Research (14 papers) and Adolescent and Pediatric Healthcare (12 papers). The work is most often cited by research in Rheumatology (4.5k citations), Hematology (2.0k citations), Immunology (2.4k citations), Genetics (527 citations) and Dermatology (220 citations). H. Küpper has collaborated with scholars based in Germany, United States and Netherlands. Frequent co-authors include Robert Wong, Désirée van der Heijde, Joachim Sieper, S. Kary, Martín Rudwaleit, Jürgen Braun, Alan Kivitz, Maxime Dougados, John C. Davis and Paul Emery. Their work appears in journals such as Annals of the Rheumatic Diseases, Lara D. Veeken, The Journal of Rheumatology, Arthritis Research & Therapy and Arthritis & Rheumatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact